Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2017-02-15Clinical Trial Update: A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma [Phase 2]
The open-label Phase 2 trial of ultra-high-dose dexamethasone for relapsed multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-01-23Clinical Trial Update: UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination [Phase 2]
University of Arkansas announced the withdrawal of a Phase II trial evaluating a novel proteasome inhibitor and IMiD combination for multipl…
-
CLINICAL_TRIALS withdrawal · 2017-01-20Clinical Trial Update: Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma [Phase 4]
Phase 4 trial evaluating vertebral compression fracture fixation with RF kyphoplasty in patients with multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-12-19Clinical Trial Update: Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant [Phase 2]
A Phase 2 study evaluating carfilzomib with dexamethasone in multiple myeloma patients who previously underwent a stem cell transplant was w…
-
CLINICAL_TRIALS withdrawal · 2016-12-15Clinical Trial Update: Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma [Phase 1]
Phase 1 trial evaluating a combination of bortezomib, arsenic trioxide, and melphalan in patients undergoing autologous stem cell transplant…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2016-11-08Clinical Trial Update: Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma [Phase 2]
A Phase 2 trial evaluating panobinostat in combination with carfilzomib and dexamethasone for relapsed and/or refractory multiple myeloma ha…
-
CLINICAL_TRIALS withdrawal · 2016-10-07Clinical Trial Update: Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma [Phase 1, Phase 2]
A Phase 1b/2 study evaluating Radium-223 dichloride in combination with Bortezomib and Dexamethasone for relapsed multiple myeloma has been …
-
CLINICAL_TRIALS withdrawal · 2016-09-01Clinical Trial Update: A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma [Phase 2]
Phase IIa trial evaluating sotatercept for bone mass and turnover in patients with multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-07-14Clinical Trial Update: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies [Phase 2]
A Phase 2 clinical trial evaluating single or double donor umbilical cord blood transplant for high-risk hematologic malignancies has been w…
-
CLINICAL_TRIALS withdrawal · 2016-07-12Clinical Trial Update: Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma [EARLY_Phase 1]
The clinical trial NCT02447055 evaluating allogeneic stem cell transplantation for multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-05-10Clinical Trial Update: Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy [Phase 2]
Phase 2 trial evaluating vorinostat plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in multiple myeloma patients w…
-
CLINICAL_TRIALS withdrawal · 2016-05-03Clinical Trial Update: Chemotherapy-Induced Peripheral Neuropathy Survey
A clinical trial evaluating chemotherapy-induced peripheral neuropathy has been withdrawn. The study involved patients with breast cancer, c…
-
CLINICAL_TRIALS withdrawal · 2016-04-07Clinical Trial Update: UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib [Phase 2]
A Phase II open-label study evaluating the overall response rate of trametinib in multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-02-12Clinical Trial Update: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma [Phase 2]
A Phase 2 trial of SOM230 LAR in combination with bortezomib and dexamethasone for refractory or relapsed multiple myeloma has been withdraw…
-
CLINICAL_TRIALS withdrawal · 2015-10-26Clinical Trial Update: UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies [Phase 1]
A phase 1 clinical trial (UARK 2006-28) of human cord blood transplantation in advanced hematological malignancies has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-08-19Clinical Trial Update: Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy [Phase 2]
A Phase 2 clinical trial evaluating monoclonal antibody therapy or biological therapy in patients with chronic lymphocytic leukemia or multi…
-
CLINICAL_TRIALS withdrawal · 2015-06-08Clinical Trial Update: Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment [Phase 1]
Phase 1 trial evaluating total marrow and total lymph node irradiation with fludarabine and melphalan followed by donor stem cell transplant…
-
CLINICAL_TRIALS withdrawal · 2015-05-29Clinical Trial Update: Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
A clinical trial evaluating perceived burden in late-stage cancer patients and their caregivers has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-04-24Clinical Trial Update: Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma [Phase 2]
Phase 2 trial of bortezomib, dexamethasone, and cyclophosphamide for older patients with multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-04-14Clinical Trial Update: Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. [Phase 4]
This clinical trial update states that a Phase 4 open-label study of zoledronic acid in patients with bone lesions due to multiple myeloma h…
-
CLINICAL_TRIALS withdrawal · 2015-04-06Clinical Trial Update: A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib [Phase 2]
Phase 2 study evaluating bortezomib in combination with pegylated liposomal doxorubicin for relapsed multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-03-24Clinical Trial Update: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
This entry describes an expanded-access, multi-center, single-arm, open-label study of plerixafor for patients with non-Hodgkin's lymphoma, …
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
A SWOG phase 2 trial evaluating a combination of bortezomib, thalidomide, lenalidomide, and autologous stem cell transplant for newly diagno…
-
CLINICAL_TRIALS withdrawal · 2015-03-04Clinical Trial Update: A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
This phase I/II trial evaluated a combination of liposomal doxorubicin, melphalan, and bortezomib in relapsed/refractory multiple myeloma, b…
-
EMA withdrawal · 2014-11-20EMA Application withdrawn: Neofordex (dexamethasone) — Laboratoires CTRS - Boulogne Billancourt
Application for Neofordex (dexamethasone) withdrawn by Laboratoires CTRS for multiple myeloma.